The Galilee Research Institute (MIGAL) had been working on a vaccine against infectious bronchitis virus (IBV) in poultry over the past few years. Apparently, that poultry virus is similar to the Wuhan Virus spreading globally. The MIGAL’s scientists were able to tweak that vaccine for the COVID-19 coronavirus given that the illness has similar genes and manner of infecting cells. The Israeli scientists believe they will be able to produce a COVID-19 vaccine during the next 8-10 weeks and achieve safety approval in 90 days.
The Jpost reported:
“Let’s call it pure luck,” he said. “We decided to choose coronavirus as a model for our system just as a proof of concept for our technology.”
But after scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one and that it uses the same infection mechanism, which increases the likelihood of achieving an effective human vaccine in a very short period of time, Katz said.
“All we need to do is adjust the system to the new sequence,” he said. “We are in the middle of this process, and hopefully in a few weeks, we will have the vaccine in our hands. Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.”
Of course, even if the vaccine is produced on schedule, many in Bernie Sanders’ campaign will still be vulnerable to the disease. People in his campaign such as Ilhan Omar, Linda Sarsour, James Zogby, AOC, Phillip Agnew, and others support the anti-Semitic BDS movement and thus boycott all products from Israel. So unless they are hypocrites they are sh*t out of luck.
Other supporters of BDS who may avoid the vaccine include Reps Rashida Tlaib (D-MI), Mark Pocan (D-WI), Black Lives Matter, Cornel West, Roger Waters and sadly many more.
The Galilee Research Institute explained their research:
After 4 years of multi-disciplinary research funded by Israel’s Ministry of Science and Technology in cooperation with Israel’s Ministry of Agriculture, MIGAL has achieved a scientific breakthrough that will lead to the rapid creation of a vaccine against Coronavirus. This possibility was identified as a by-product of MIGAL’s development of a vaccine against IBV (Infectious Bronchitis Virus), a disease affecting poultry, whose effectiveness has been proven in pre-clinical trials carried out at the Volcani Institute. MIGAL has now made required genetic adjustments to adapt the vaccine to COVID-19, the human strain of coronavirus, and is working to achieve the safety approvals that will enable in-vivo testing, enable the initiation of production of a vaccine to counter the Coronavirus epidemic currently spreading throughout the world, which so far has claimed 2,666 lives.
From research conducted at MIGAL, it has been found that the poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism, a fact that increases the likelihood of achieving an effective human vaccine in a very short period of time.
Commenting on the news, David Zigdon, CEO of MIGAL GALILEE RESEARCH INSTITUTE, said, “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days. This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion final product development and regulatory activities.”
Dr. Chen Katz, MIGAL’s Biotechnology Group Leader, commented, “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis (a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material), causing the body to form antibodies against the virus. In pre-clinical (IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies.
